We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10.11%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$47.1B
AUM Growth
+$2.61B
(+5.9%)
Cap. Flow
-$501M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
14.43%
Holding
3,576
New
705
Increased
706
Reduced
825
Closed
988
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walmart Inc
WMT
|
+$417M |
| 2 |
Meta Platforms (Facebook)
META
|
+$383M |
| 3 |
Amazon
AMZN
|
+$308M |
| 4 |
Microsoft
MSFT
|
+$293M |
| 5 |
GE Aerospace
GE
|
+$263M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$312M |
| 2 |
Bank of America
BAC
|
+$292M |
| 3 |
ExxonMobil
XOM
|
+$274M |
| 4 |
lululemon athletica
LULU
|
+$238M |
| 5 |
Qualcomm
QCOM
|
+$228M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.05% |
| 2 | Technology | 14.35% |
| 3 | Consumer Discretionary | 13.97% |
| 4 | Financials | 9.9% |
| 5 | Industrials | 6.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Copart
CPRT
$25.9B
| $17.6M | 0.04% |
468,290
+414,138
| +765% | +$14.1M |
|
502
Thermo Fisher Scientific
TMO
$211B
| $17.6M | 0.04% |
30,479
-370,095
| -92% | -$209M |
|
503
Nordic American Tanker
NAT
$1.37B
| $17.5M | 0.04% |
+4,410,866
| New | +$15.8M |
|
504
State Street Consumer Staples Select Sector SPDR ETF
XLP
$14.2B
| $17.4M | 0.04% |
+233,474
| New | +$17.1M |
|
505
Rogers Corp
ROG
$2.33B
| $17.3M | 0.04% |
105,796
-150,829
| -59% | -$21.8M |
|
|
ETRN
506
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $17.3M | 0.04% |
2,990,162
-301,823
| -9% | -$1.93M |
|
507
Danaos Corp
DAC
$2.55B
| $17.2M | 0.04% |
315,120
+37,512
| +14% | +$2.13M |
|
|
ETNB
508
DELISTED
89bio
ETNB
| $17.2M | 0.04% |
1,129,471
-357,840
| -24% | -$4.67M |
|
509
Stryker
SYK
$127B
| $17.2M | 0.04% |
60,186
-199,867
| -77% | -$53M |
|
510
Lufax Holding
LU
$1.2B
| $17M | 0.04% |
2,087,421
-1,645,081
| -44% | -$15.8M |
|
511
FerroAtlántica
GSM
$628M
| $16.7M | 0.04% |
3,372,374
-1,237,948
| -27% | -$5.71M |
|
|
CNDA
512
DELISTED
Concord Acquisition Corp II
CNDA
| $16.6M | 0.04% |
1,640,423
-125
| -0% | -$1.26K |
|
513
Nutanix
NTNX
$14.9B
| $16.6M | 0.04% |
637,132
-43,225
| -6% | -$1.17M |
|
514
Array Technologies
ARRY
$818M
| $16.5M | 0.04% |
755,480
-163,150
| -18% | -$3.34M |
|
515
Neurocrine Biosciences
NBIX
$17.7B
| $16.5M | 0.04% |
162,683
+132,237
| +434% | +$13.8M |
|
516
Toronto Dominion Bank
TD
$198B
| $16.4M | 0.03% |
273,622
+79,514
| +41% | +$5.14M |
|
517
RPM International
RPM
$13.7B
| $16.3M | 0.03% |
187,213
+180,319
| +2,616% | +$15.8M |
|
518
Berkshire Hathaway Class B
BRK.B
$1.07T
| $16.3M | 0.03% |
52,807
+32,223
| +157% | +$9.93M |
|
519
CALL
State Street Energy Select Sector SPDR ETF
XLE
$39.7B
| $16.3M | 0.03% |
393,200
-397,800
| -50% | -$17M |
|
520
ICICI Bank
IBN
$106B
| $16.2M | 0.03% |
+752,796
| New | +$15.7M |
|
521
FIVE9
FIVN
$1.77B
| $16.2M | 0.03% |
+224,099
| New | +$16M |
|
522
PUT
Advanced Micro Devices
AMD
$851B
| $16.1M | 0.03% |
164,000
+17,900
| +12% | +$1.46M |
|
523
Trupanion
TRUP
$1.05B
| $16.1M | 0.03% |
374,377
+94,012
| +34% | +$5.09M |
|
524
AutoZone
AZO
$48.3B
| $16M | 0.03% |
6,527
-14,771
| -69% | -$36M |
|
525
Global Ship Lease
GSL
$1.57B
| $16M | 0.03% |
856,071
-112,556
| -12% | -$2.1M |
|
Similar funds
Marshall Wace's Q1 2023 Portfolio in Review
As of Q1 2023, Marshall Wace held 3,576 positions worth $47.1B, up 5.9% from $44.5B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Marshall Wace's Q1 2023 filing shows 705 new, 706 increased, 825 reduced and 988 closed positions. Its largest new stake was Madrigal Pharmaceuticals: 541,764 shares worth $131M. The largest sale was Cigna, an estimated $312M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
- Marshall Wace's largest Q1 2023 buy was Madrigal Pharmaceuticals: 541,764 shares worth $131M.
- Marshall Wace added most to Walmart Inc in Q1 2023, an estimated $417M increase.
- Marshall Wace's biggest Q1 2023 reduction was Cigna, cutting an estimated $312M.
- Marshall Wace fully exited Merck in Q1 2023, selling an estimated $115M.
- Marshall Wace's ten largest holdings make up 14% of its $47.1B portfolio in Q1 2023.
- Marshall Wace opened 705 new positions and closed 988 in Q1 2023.
- Marshall Wace's portfolio value rose 5.9% quarter-over-quarter to $47.1B.
Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.